CHICAGO — Edward S. Kim, MD, chair of the department of solid tumor oncology at Levine Cancer Institute at Carolinas Healthcare System and a HemOnc Today Editorial Board member, discusses various advances within the treatment landscape of lung cancer at the ASCO Annual Meeting.
This is an “exciting time” for the field of lung cancer following various FDA approvals, the development of multiple agents, and investigations into the use of immunotherapies and combination regimens, Kim said.
“These studies further expand on our information, knowledge and options for patients,” he said. “Everything about this [aims] to try to get more options for our patients with lung cancer. We want to incorporate precision medicine, large genome panels, blood-based markers. ... These are all exciting developments, that are occurring and being discussed at ASCO, and there will be many more things to come with lung cancer later this year.” – by Kristie L. Kahl
Disclosure: Kim reports no relevant financial disclosures.